



US 20210155712A1

(19) **United States**(12) **Patent Application Publication****Boyd-Kirkup et al.**(10) **Pub. No.: US 2021/0155712 A1**(43) **Pub. Date: May 27, 2021**(54) **TREATMENT AND PREVENTION OF
CANCER USING HER3 ANTIGEN-BINDING
MOLECULES**(30) **Foreign Application Priority Data**

Sep. 11, 2019 (GB) 1913079.8

(71) Applicant: **Hummingbird Bioscience Holdings
Pte. Ltd., Singapore (SG)****Publication Classification**(72) Inventors: **Jerome Douglas Boyd-Kirkup,**
Singapore (SG); **Siyu Guan,** Singapore
(SG); **Piers Ingram,** Singapore (SG);
Konrad Paszkiewicz, Singapore (SG);
Vicente Sancenon, Singapore (SG);
Dipti Thakkar, Singapore (SG);
Zhihao Wu, Singapore (SG)(51) **Int. Cl.****C07K 16/32** (2006.01)**A61P 35/00** (2006.01)(52) **U.S. Cl.**CPC **C07K 16/32** (2013.01); **A61P 35/00**
(2018.01); **C07K 2317/76** (2013.01); **C07K**
2317/515 (2013.01); **C07K 2317/51** (2013.01);
C07K 2317/565 (2013.01)(73) Assignee: **Hummingbird Bioscience Holdings
Pte. Ltd., Singapore (SG)**

(57)

ABSTRACT(21) Appl. No.: **17/153,705**

Methods for treating or preventing a cancer in a subject are disclosed, wherein the cancer comprises cells having a mutation resulting in increased expression of a ligand for HER3, wherein the method comprises administering a therapeutically or prophylactically effective amount of an antigen-binding molecule which is capable of binding to HER3 to the subject.

(22) Filed: **Jan. 20, 2021****Specification includes a Sequence Listing.****Related U.S. Application Data**(63) Continuation of application No. PCT/EP2020/
075319, filed on Sep. 10, 2020.